F070 The Changing Landscape of Early-Stage Melanoma Management
DESCRIPTION
There have been many recent advances in our understanding of potential therapeutic and management options for patients with early-stage melanoma (ie, melanoma confined only to the skin). This session will discuss how to incorporate this information into practice, as well as discuss relevant clinical trials. Topics include a review of recent clinical and dermatopathologic literature, guidelines for germline genetic testing, the potential role of the gut biome in melanoma, novel diagnostic technologies, and implications for surgical management of melanoma in the context of novel systemic therapies and emerging technologies.
LEARNING OBJECTIVES
Describe some of the recent melanoma literature, both clinically-oriented and dermatopathology-oriented
Discuss germline genetic testing guidelines, the potential role of the gut biome in melanoma, and novel diagnostic techniques, including artificial intelligence and newer devices
Describe implications for surgical management of melanoma in the context of novel systemic therapies and emerging technologies
SCHEDULE
9:00 AM
Introduction
Michael E. Ming, MD, FAAD
9:05 AM
Lessons from the recent melanoma literature
Michael E. Ming, MD, FAAD
9:25 AM
Novel diagnostic techniques in melanoma
Rebecca I Hartman, MD, MPH, FAAD
9:45 AM
Melanoma dermatopathology update
Emily Y. Chu, MD, PhD, FAAD
10:05 AM
Melanoma update: from genes to germs
Kelly C Nelson, MD, FAAD
10:25 AM
Surgery for melanoma: where we are and where we are going
Giorgos Karakousis, MD
10:45 AM
Q&A
DIRECTOR
Michael E. Ming, MD, FAAD
SPEAKERS
Emily Y. Chu, MD, PhD, FAAD
Rebecca I Hartman, MD, MPH, FAAD
Giorgos Karakousis, MD
Kelly C Nelson, MD, FAAD
DISCLOSURES
Emily Y. Chu, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Rebecca I Hartman, MD, MPH, FAAD
Almirall – Consultant (1099 relationship)(Fees); Evereden – Advisory Board(Stock), Consultant(Fees); Med Learning Group – Speaker/Faculty Education(Fees); MJH Life Sciences – Consultant (1099 relationship)(Fees); Oasis Pharmaceuticals – Data Safety Monitoring Board(Fees); Zura Bio – Data Safety Monitoring Board(Fees);
Giorgos Karakousis, MD
Merck – Investigator(Grants/Research Funding);
Michael E. Ming, MD, FAAD
No financial relationships exist with ineligible companies.
Kelly C Nelson, MD, FAAD
No financial relationships exist with ineligible companies.